Fisiopatología, factores de riesgo y tratamientos | 12 OCT 21

COVID-19 prolongado

COVID-19 podría persistir hasta en el 10% de los pacientes.
Autor/a: Shin Jie YongReadSpeaker webReader: ListenFocusReview ArticleLong COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatmentsShin Jie Yong Infectious Diseases, 53:10, 737-754
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

[1] Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID. Nat Rev Microbiol. 2020;19(3):141–154.

[2] Maxwell E. ’Living with Covid19: A dynamic review of the evidence around ongoing Covid19 symptoms (often called Long Covid).’, (updated 30th September 2020) <>, accessed 31st January 2021.

[3] Rubin R. As Their Numbers Grow, COVID-19 “Long Haulers” Stump Experts. JAMA. 2020;324(14):1381–1383.

[4] Callard F, Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426.

[5] Altmann DM, Boyton RJ. Decoding the unknowns in long covid. BMJ. 2021;372:n132.

[6] Baig AM. Deleterious outcomes in long-Hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11(24);4017–4020.

[7] Venkatesan P. NICE guideline on long COVID’. The Lancet Respiratory Medicine. 2021;9(2):129.

[8] Nath A. Long-Haul COVID. Neurology. 2020;95(13): 559–560.

[9] Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28–33. [10] Davido B, et al. Post-COVID-19 chronic symptoms: a postinfectious entity? Clin Microbiol Infect. 2020;26(11): 1448–1449.

[11] Datta SD, Talwar A, Lee JT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251–2252.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021